ALK and neuroblastoma: In addition, the assay includes recently discovered risk factors for neuroblastoma (e.g. telomere maintenance, mutations within the RAS/p53 pathways), and in particular the ALK status, and therefore is able to identify a) patients that could be treated with ALK inhibitors and b) patients with ultra-high-risk neuroblastomas.